Format

Send to

Choose Destination
Am J Surg Pathol. 2018 Feb;42(2):e11-e27. doi: 10.1097/PAS.0000000000000980.

The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.

Author information

1
Departments of Pathology.
2
Department of Pathology and Genetics, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.
3
European Salivary Gland Society, Geneva, Switzerland.
4
Department of Anatomical Pathology, University of Calgary, Foothills Medical Centre, Calgary, AB, Canada.
5
Department of Biomedical Sciences and Medicine, Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal.
6
Otorhinolaryngology.
7
Department of Oncology and Radiotherapy, Oncological Clinic, Faculty of Medicine in Plzen, Charles University.
8
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
9
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR.
10
Department of Otolarygology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
11
University of Udine School of Medicine, Udine, Italy.
12
Otorhinolaryngology-Head and Neck Surgery, University Hospitals Leuven.
13
Department of Oncology, Section Head and Neck Oncology, KU Leuven, Leuven, Belgium.
14
Department of Pathology, Allegiance Health, Jackson, MI.
15
Molecular and Genetic Laboratory, Biopticka Lab Ltd, Plzen, Czech Republic.
16
Coordinator of the International Head and Neck Scientific Group, Padua, Italy.

Abstract

Salivary gland neoplasms are a morphologically heterogenous group of lesions that are often diagnostically challenging. In recent years, considerable progress in salivary gland taxonomy has been reached by the discovery of tumor type-specific fusion oncogenes generated by chromosome translocations. This review describes the clinicopathologic features of a selected group of salivary gland carcinomas with a focus on their distinctive genomic characteristics. Mammary analog secretory carcinoma is a recently described entity characterized by a t(12;15)(p13;q25) translocation resulting in an ETV6-NTRK3 fusion. Hyalinizing clear cell carcinoma is a low-grade tumor with infrequent nodal and distant metastasis, recently shown to harbor an EWSR1-ATF1 gene fusion. The CRTC1-MAML2 fusion gene resulting from a t(11;19)(q21;p13) translocation, is now known to be a feature of both low-grade and high-grade mucoepidermoid carcinomas associated with improved survival. A t(6;9)(q22-23;p23-34) translocation resulting in a MYB-NFIB gene fusion has been identified in the majority of adenoid cystic carcinomas. Polymorphous (low-grade) adenocarcinoma and cribriform adenocarcinoma of (minor) salivary gland origin are related entities with partly differing clinicopathologic and genomic profiles; they are the subject of an ongoing taxonomic debate. Polymorphous (low-grade) adenocarcinomas are characterized by hot spot point E710D mutations in the PRKD1 gene, whereas cribriform adenocarcinoma of (minor) salivary glands origin are characterized by translocations involving the PRKD1-3 genes. Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma with morphologic and molecular features akin to invasive ductal carcinoma of the breast, including HER2 gene amplification, mutations of TP53, PIK3CA, and HRAS and loss or mutation of PTEN. Notably, a recurrent NCOA4-RET fusion has also been found in SDC. A subset of SDC with apocrine morphology is associated with overexpression of androgen receptors. As these genetic aberrations are recurrent they serve as powerful diagnostic tools in salivary gland tumor diagnosis, and therefore also in refinement of salivary gland cancer classification. Moreover, they are promising as prognostic biomarkers and targets of therapy.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center